Nirvana Life Sciences Inc. (CSE:NIRV)

Nirvana Life Sciences Income Statement

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2025	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Selling, General & Admin	0.35	0.32	0.4	0.79	0.43	0.28
Research & Development	-	-	0.12	0.09	0.32	0.39
Operating Expenses	0.36	0.34	0.71	1.18	1.16	0.7
Operating Income	-0.36	-0.34	-0.71	-1.18	-1.16	-0.7
Interest Expense	-	-	-0	-0.01	-	-
Interest & Investment Income	0	-	-	0	0.01	0
Other Non Operating Income (Expenses)	-0.03	-0.03	-0.03	-0.08	-4.5	-0.03
EBT Excluding Unusual Items	-0.39	-0.37	-0.74	-1.26	-5.66	-0.73
Asset Writedown	-	-	-0.16	-0.25	-	-
Other Unusual Items	0.01	-	0.03	0.02	-	-
Pretax Income	-0.38	-0.37	-0.87	-1.49	-5.66	-0.73
Earnings From Continuing Operations	-0.38	-0.37	-0.87	-1.49	-5.66	-0.73
Minority Interest in Earnings	-0	0	0	0	0	-
Net Income	-0.38	-0.37	-0.87	-1.49	-5.65	-0.73
Net Income to Common	-0.38	-0.37	-0.87	-1.49	-5.65	-0.73
Shares Outstanding (Basic)	23	5	5	3	4	3
Shares Outstanding (Diluted)	23	5	5	3	4	3
Shares Change (YoY)	-13.60%	3.26%	37.61%	-7.05%	5.19%	-
EPS (Basic)	-0.02	-0.08	-0.19	-0.44	-1.55	-0.21
EPS (Diluted)	-0.02	-0.08	-0.19	-0.44	-1.55	-0.21
Free Cash Flow	-1.06	-0.07	-0.19	-0.33	-0.49	-1.2
Free Cash Flow Per Share	-0.05	-0.01	-0.04	-0.10	-0.13	-0.35
EBITDA	-	-0.32	-0.7	-1.08	-1.07	-0.67
D&A For EBITDA	-	0.02	0.02	0.09	0.09	0.03
EBIT	-0.36	-0.34	-0.71	-1.18	-1.16	-0.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.